Home LiteratureArticle Details
PMID: 1545108 Published · ppublish English Journal Article

Resistance to imipenem among selected gram-negative bacilli in the United States.

Infection control and hospital epidemiology ·Vol. 13 ·No. 1 ·1992-01-00 ·Pages 10-4

Gaynes RP, Culver DH

Abstract

Identification of imipenem resistance among selected gram-negative bacilli, especially Pseudomonas aeruginosa and Enterobacter species. We analyzed 1986-1990 National Nosocomial Infection Surveillance (NNIS) data from 3,316 P aeruginosa isolates and 1,825 Enterobacter species isolates for which susceptibility results to imipenem were reported. For P aeruginosa, 11.1% of the isolates were resistant to imipenem; 16.1% were either intermediate-susceptible or resistant to the drug. A logistic regression model found that resistance was more common among P aeruginosa isolated from the respiratory tract, patients in intensive care units, and in teaching hospitals. Additionally, resistance to imipenem increased by 25% in teaching hospitals from 1986-1988 to 1989-1990. For Enterobacter species, 1.3% of the isolates were resistant to imipenem; 2.3% were either intermediate-susceptible or resistant to the drug. However, imipenem resistance for these isolates did not differ between the two periods and was not more common in patients in an intensive care unit or infections at any specific site. The frequency of resistance to imipenem is greater among P aeruginosa than among Enterobacter species. Resistance to imipenem among the P aeruginosa isolates is more common from strains isolated from patients with nosocomial infections in an intensive care unit, from the respiratory tract, and from teaching hospitals. Resistance appears to be increasing among nosocomial P aeruginosa isolated in teaching hospitals.

MeSH Terms
Ceftazidime/pharmacology,therapeutic use Cross Infection/drug therapy,microbiology Drug Resistance, Microbial Enterobacter/drug effects,isolation & purification Enterobacteriaceae Infections/drug therapy,microbiology Humans Imipenem/pharmacology,therapeutic use Logistic Models Microbial Sensitivity Tests Pseudomonas Infections/drug therapy,microbiology Pseudomonas aeruginosa/drug effects,isolation & purification United States
Chemicals
Imipenem Ceftazidime
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Gaynes R P
Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia 30333.
Culver D H
Article Info
Journal
Infection control and hospital epidemiology
Abbr.
Infect Control Hosp Epidemiol
ISSN
0899-823X
Published
1992-01-00
Pages
10-4
Language
English
Region
United States
NLM ID
8804099
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com